Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Post by mercedesmanon Jun 15, 2022 4:20pm
164 Views
Post# 34759368

Stock Dividend or Dialco Spinout ?

Stock Dividend or Dialco Spinout ?If (when?) there is a sale of the Dialco assets, you have to wonder if there will be a sale to mysterious 3rd party before Dialco is spun out to a separte trading entity (ie before the sale, a dividend of shares in Dialco to all Spectral shareholders) or whether there would be a straight sale of assets, out of the one entity (Spectral).  In the latter case, coffers would be filled with cash and then need to be divvied out to shareholders...assuming, of course, that they don't give it away.

Fresenius paid $ 2B USD for NxStage.  Before all their recent problems, Outset was valued at almost $ 2B USD as well.

Makes you wonder what a "game-changer" might be worth, in this new paradigm of HHD.

MM
<< Previous
Bullboard Posts
Next >>